Insignis Investigations' Director said, "We're particularly pleased to have achieved British Standard 102000 certification as it underlines our commitment to our customers and our focus on quality.

NORTH HAVEN, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Insignis Therapeutics, a leader in innovative allergy and anaphylaxis treatments, announced today that it has received positive feedback from ...

NORTH HAVEN, Conn. and NEW HAVEN, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Insignis Therapeutics (“Insignis”), a biotech company focused on developing innovative therapeutics for anaphylaxis ...

The Insignis –26G™ Subcutaneous Needle Sets are FDA cleared in the U.S. and IHS expects to receive full regulatory clearance for the entire Insignis™ system in the next few weeks.